[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hair-pulling\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hair-pulling":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100614682",false,"NCT07282769","Semaglutide (Wegovy) Treatment for Trichotillomania","Once Weekly Semaglutide Treatment of Trichotillomania: An Open-Label Study","Inclusion Criteria:\n\n1. Men and women age 18-75;\n2. Diagnosis of current trichotillomania based on DSM-5 criteria and confirmed using the clinician-administered MIDI (13);\n3. Hair pulling daily with urges to pull as the trigger in \\>50% of the episodes of pulling;\n4. Women of childbearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;\n5. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence\n\nExclusion Criteria:\n\n1. Infrequent pulling (i.e. less than daily) or automatic pulling (i.e. no urges to pull);\n2. Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;\n3. History of seizures;\n4. Myocardial infarction within 6 months;\n5. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;\n6. A need for medication other than semaglutide with possible psychotropic effects or unfavorable interactions as determined by the investigator;\n7. Clinically significant suicidality (defined by the Columbia Suicide-Severity Rating Scale);\n8. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder;\n9. Current skin picking disorder;\n10. Initiation of psychotherapy or behavior therapy within 3 months prior to study baseline;\n11. Initiation of psychotropic medications within 3 months prior to study baseline (stable doses will be allowed);\n12. Previous treatment with semaglutide;\n13. Use of any weight loss medications;\n14. Body mass index (BMI, calculated as weight in kilograms divided by height in meters squared) less than 23;\n15. Past-year substance use disorder other than tobacco use disorder or mild cannabis use disorder;\n16. Recent (30-day) use of illicit drugs except cannabis;\n17. History of diabetes, and current medical or neurological illness precluding participation based on physician judgment;\n18. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2A or 2B;\n19. History of pancreatitis.","ALL","18 Years","75 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This research study is testing the effectiveness and safety of semaglutide (Wegovy) in people with trichotillomania, also known as hair-pulling disorder.",[26,27,28,29,30],"Trichotillomania (Hair-Pulling Disorder)","Trichotillomania","Hair Pulling Disorder","Hair Pulling","Hair-Pulling Disorder",[32,33],"trichotillomania","hair pulling","NOT_YET_RECRUITING","2026-06-08",{"date":37,"type":38},"2026-06-10","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2027-02",{"name":44,"class":45},"University of Chicago","OTHER",""]